{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-25-006210","form_type":"8-K","ticker":"NTHI","cik":"0001979414","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.748740+00:00","generated_at":"2026-05-17T14:01:33.167752+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeOnc secures $2.5M NIH grants for NEO212; finalizes $50M Quazar partnership","bullets":["Awarded two NIH STTR grants totaling $2.5M to advance NEO212 in gliomas and leukemia.","$400K Phase 1 grant supports NEO212 preclinical study in AML; $2.1M Phase 2 grant targets newly diagnosed gliomas.","NuroMENA Holdings Ltd. incorporated by Abu Dhabi Global Market, clearing all contingencies for $50M investment from Quazar Investment.","Partnership will fund CNS platform launch in MENA region and accelerate NEO212/NEO100 clinical programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-25-006210","json":"https://secwatch.observer/filing/0001829126-25-006210.json","markdown":"https://secwatch.observer/filing/0001829126-25-006210.md","text":"https://secwatch.observer/filing/0001829126-25-006210.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1979414/000182912625006210/0001829126-25-006210-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1979414/000182912625006210/neonctechnologies_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:01:33.167752+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}